Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Atenolol Associated With Lower MACE Risk After MI Than BisoprololAmong patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality, compared with bisoprolol, according to an observational cohort study published Sept. 22 in NEJM Evidence.
- ACC/AHA Joint Guideline Committee Reaffirms Perioperative GuidelineAfter evaluating new evidence published over the last two years on perioperative cardiovascular management of patients following noncardiac surgery, the ACC/AHA Joint Committee on Clinical Practice Guidelines has determined that the most recent perioperative guideline published in 2024 “remains valid and current.†Read the full guideline published in JACC.
- ACCEL Lite: PRESC1SE-MI: Efficacy of the ESC 0/1-hour PathwayIn this episode, Jeroen J. Bax PhD, MD, FACC and Jasper Boeddinghaus, MD discuss “PRESC1SE-MI: Safety and efficacy of the ESC 0/1-hour Pathwayâ€.
- Statins For the Prevention of Anthracycline-Induced Cardiotoxicity: Contextualizing Guideline Recommendations For Clinical PracticeAnthracycline-induced cardiotoxicity is a major contributor to long-term cardiovascular (CV) outcomes in survivors of cancer. Up to 20% of patients exposed to anthracyclines develop irreversible cardiomyopathy through mechanisms leading to cardiomyocyte death.
- PAD Series Spotlights Current Burden, Future ChallengesA three-part series published Sept. 22 in The Lancet underscores the growing global impact of peripheral artery disease (PAD) and reinforces the need for earlier diagnosis, improved treatment and better access to care.